PTC Therapeutics (PTCT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $197 million, with $124 million from the DMD franchise, $72.3 million from Translarna, and $52 million from Emflaza, reflecting strong commercial execution despite competitive and regulatory pressures.

• Royalty revenue from Evrysdi was $61.4 million in Q3, up 22% year-over-year, while manufacturing revenue dropped to zero after the gene therapy manufacturing business sale.

• Net loss for Q3 2024 was $106.7 million, improved from $133.0 million in Q3 2023; cash and equivalents totaled over $1 billion as of September 30, 2024.

• Advanced late-stage programs with FDA filings for sepiapterin, Translarna, and AADC gene therapy, and a planned NDA for vatiquinone in December 2024.

• Maintained a diversified rare disease portfolio and strong R&D momentum, positioning for up to four potential U.S. launches in 2025.

Financial highlights

• Q3 2024 total revenue was $197 million, nearly flat year-over-year; net product revenue was $135.4 million, while royalty revenue from Evrysdi was $61.4 million.

• Non-GAAP R&D expense was $152 million; GAAP R&D expense was $161.4 million; non-GAAP SG&A expense was $63 million; GAAP SG&A expense was $73.5 million.

• Gross margin for Q3 2024 was 92%.

• Net loss per share for Q3 2024 was $1.39, improved from $1.76 in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $1.01 billion as of September 30, 2024.

Outlook and guidance

• 2024 total revenue guidance raised to $750–800 million, reflecting confidence in continued strong performance.

• Multiple product launches anticipated in 2025, including sepiapterin, Translarna, vatiquinone, and AADC gene therapy.

• GAAP R&D and SG&A expenses for 2024 expected between $740 million and $835 million, including up to $65 million in R&D milestone payments.

• Company expects existing cash and product sales to fund operations for at least the next twelve months.

• Emflaza revenue expected to decline further due to generic competition after loss of orphan drug exclusivity.